Noguchi M et al. – Elevated IL–6 levels before vaccination was an unfavorable factor for overall survival of Docetaxel–based chemotherapy–resistant castration–resistant prostate cancer patients as well as all 42 patients with personalized peptide vaccine by multivariable analysis. Control of elevated IL–6 by combined therapy may provide much better clinical outcome. [more...]
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close